

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended): A stent for in vivo placement, said stent comprising being formed in a substantially tubular shape and expandable in the outward radial direction of the substantially tubular shape, containing a material nondegradable in vivo, and a poly (lactide-co-glycolide) on at least a portion of the surface thereof, wherein the weight of the poly (lactide-co-glycolide) being on the stent is 3  $\mu\text{g}/\text{mm}$  to 80  $\mu\text{g}/\text{mm}$  per unit length in the axial direction of the stent.

2. (Original): The stent according to claim 1, wherein the poly (lactide-co-glycolide) is on either the outer surface or the inner surface of the stent.

3. (Original): The stent according to claim 1, wherein the poly (lactide-co-glycolide) is over substantially the entire surface including the outer surface, the inner surface, and the side surfaces of the stent.

4. (Previously presented): The stent according to claim 1, wherein the weight-average molecular weight of the poly (lactide-co-glycolide) is 5,000 to 130,000.

5. (Previously presented): The stent according to claim 1, wherein the molar ratios of lactic acid and glycolic acid which constitute the poly (lactide-co-glycolide) are

50 mol% to 85 mol% and 15 mol% to 50 mol%, respectively.

6. (Canceled):

7. (Original): The stent according to claim 6, wherein the weight of the poly (lactide-co-glycolide) being on the stent is 7  $\mu\text{g}/\text{mm}$  to 65  $\mu\text{g}/\text{mm}$  per unit length in the axial direction of the stent.

8. (Currently Amended): A stent for in vivo placement comprising being formed in a substantially tubular shape and expandable in the outward radial direction of the substantially tubular shape, containing a material nondegradable in vivo, and a poly (lactide-co-glycolide) and an immunosuppressive agent on at least a portion of the surface thereof, wherein the total weight of the poly (lactide-co-glycolide) and the immunosuppressive agent being on the stent is 7  $\mu\text{g}/\text{mm}$  to 65  $\mu\text{g}/\text{mm}$  per unit length in the axial direction of the stent.

9. (Original): The stent according to claim 8, wherein the poly (lactide-co-glycolide) and the immunosuppressive agent are on either the outer surface or the inner surface of the stent.

10. (Original): The stent according to claim 8, wherein the stent has the poly (lactide-co-glycolide) and the immunosuppressive agent are over substantially the entire surface including the outer surface, the inner surface, and the side surfaces of the stent.

11. (Previously presented): The stent according to claim 8, wherein the weight-average molecular weight of the poly (lactide-co-glycolide) is 5,000 to 130,000.

12. (Previously presented): The stent according to claim 8, wherein the molar ratios of lactic acid and glycolic acid which constitute the poly (lactide-co-glycolide) are 50 mol% to 85 mol% and 15 mol% to 50 mol%, respectively.

13. (Previously presented): The stent according to claim 8, wherein the immunosuppressive agent is tacrolimus (FK-506), cyclosporine, sirolimus (rapamycin), azathioprine, mycophenolate mofetil, or an analogue thereof.

14. (Original): The stent according to claim 13, wherein the immunosuppressive agent is tacrolimus (FK-506).

15. (Previously presented) The stent according to claim 8, wherein the total weight of the poly (lactide-co-glycolide) and the immunosuppressive agent contained in the stent is 3 µg/mm to 80 µg/mm per unit length in the axial direction of the stent.

16. (Canceled):

17. (Previously presented): The stent according to claim 8, wherein the weight ratios of the poly (lactide-co-glycolide) and the immunosuppressive agent are 30% by weight to 80% by weight and 20% by weight to 70% by weight, respectively.

18. (Original): The stent according to claim 17, wherein the weight ratios of the poly (lactide-co-glycolide) and the immunosuppressive agent are 40% by weight to 70% by weight and 30% by weight to 60% by weight, respectively.

19. (Previously presented): The stent according to claim 8, comprising an inner layer provided on a the surface of the stent, said inner layer containing the poly (lactide-co-glycolide) and the immunosuppressive agent, and an outer layer provided on the outer surface of the inner layer, said outer layer containing only the poly (lactide-co-glycolide).